2019 International Congress Archives - Page 18 of 217

1:45pm-3:15pm: Daytime sleepiness in Parkinson’s disease: an indicator of impaired activities of daily living

T. Canento, J. Tan, B. Cruse, C. Wools, M. Ghaly, M. Beckley, F. Leen, AH. Evans (Melbourne, Australia)

Quality of Life · Les Muses Terrace, Level 3

1:45pm-3:15pm: Decreased serum alpha-synuclein in patients with Restless Legs Syndrome and association with SNCA-Rep1 polymorphism

YC. Wu, XY. Zhu, TT. Wu, T. Liu, HM. Wang, YJ. Chen, X. Li, XX. Cui (Shanghai, China)

Restless Leg Syndrome, RBD and Other Sleep Disorders · Les Muses Terrace, Level 3

1:45pm-3:15pm: Deep Brain Stimulation in Early-Stage Parkinson’s Disease Provides Long-Term Rest Tremor Benefit Through Five Years

M. Hacker, M. Turchan, T. Davis, F. Phibbs, P. Hedera, P. Konrad, D. Charles (Nashville, TN, USA)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Defence Mechanism of Ego and Coping Strategy Style of the Patient with Parkinson’s Disease

M. Kulsum, S. Choudhury, A. Ghosh, P. Ghosh (Kolkata, India)

Psychiatric Manifestations · Les Muses Terrace, Level 3

1:45pm-3:15pm: Dementia with Lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile

S. Lerche, G. Machetanz, I. Wurster, B. Roeben, M. Zimmermann, A. Pilotto, A-K. Hauser, C. Schulte, I. Lachmann, T. Gasser, D. Berg, W. Maetzler, K. Brockmann (Tübingn, Germany)

Genetics · Les Muses Terrace, Level 3

1:45pm-3:15pm: Dentatorubral-Pallidoluysian Atrophy outside of Asia: A case report of the first Austrian family harbouring this rare mutation

M. Amprosi, W. Nachbauer, E. Indelicato, A. Eigentler, G. Puttinger, J. Gusenleitner, T. von Oertzen, S. Boesch (Innsbruck, Austria)

Ataxia · Les Muses, Level 3

1:45pm-3:15pm: Depression in Parkinson’s diseaese: Experience of the neurology department in Mohammed VI third level university hospital

H. El Yachkouri, M. Chraa, N. Kissani (Marrakesh, Morocco)

Psychiatric Manifestations · Les Muses Terrace, Level 3

1:45pm-3:15pm: Design and Baseline Characteristics of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study

S. Chung, M. Garriga, M. Ceravolo, N. Tambasco, W. Robieson, M. Facheris, O. Sánchez-Soliño, L. Barbato (Seoul, Republic of Korea)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism

S. Jain, A. Jain, SB. Bhargav (Sagar, India)

Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3

1:45pm-3:15pm: Detecting unsuspected mitochondrial disease: an algorithmic approach

N. Pulley, C. Condon, I. Haq (Winston-Salem, NC, USA)

Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3